SEEL Overview

Matthew Zorn's New Role: Attorney Matthew Zorn, known for his advocacy in cannabis and psychedelics policy, has been appointed as Deputy General Counsel at the U.S. Department of Health and Human Services, focusing on psychedelics policy, marking a significant shift from litigation to federal policymaking.

Impact on Psychedelics Research: Zorn's appointment is expected to enhance support for psychedelic-assisted therapy, particularly for veterans, as the new administration prioritizes exploring the therapeutic potential of psychedelics, with recent statements from the FDA and VA indicating positive outcomes from related studies.

Annual Meeting Postponement: Seelos Therapeutics has postponed its 2024 Annual Meeting of Stockholders to November 25, 2024, due to anticipated lack of quorum and to allow more time for proxy solicitation. The meeting will be held virtually.

Voting Recommendations: The Board of Directors recommends stockholders vote in favor of the nominees and proposals outlined in the proxy statement, urging those who haven't voted to do so before the new meeting date.

U.S. Stock Market Performance: U.S. stocks declined, with the Nasdaq Composite dropping around 150 points; the Dow fell by 0.30%, the NASDAQ by 0.84%, and the S&P 500 by 0.43%. Real estate shares rose by 2% while energy shares decreased by 2.3%.

Company Earnings Highlights: Johnson & Johnson reported strong third-quarter results, beating earnings expectations, while Wolfspeed, MeiraGTx Holdings, and Ericsson saw significant stock increases due to positive announcements. Conversely, Seelos Therapeutics faced a 43% drop after announcing delisting from Nasdaq.

Delisting from Nasdaq: Seelos Therapeutics has received a notice from the Nasdaq Hearings Panel to delist its common stock due to failure to meet minimum stockholder equity requirements, with trading suspended starting October 16, 2024.

PTSD Clinical Trial: The company recently signed an agreement for a clinical trial with the Department of Defense to evaluate its compound SLS-002 for PTSD in military members and veterans.

U.S. Stock Market Performance: U.S. stocks declined mid-trading, with the Dow Jones falling 150 points, while real estate shares rose by 1.5% and energy shares dropped by 2%.

Company Earnings Highlights: Goldman Sachs reported better-than-expected revenue for Q3, while Wolfspeed and MeiraGTx saw significant stock increases due to funding announcements and positive study results, respectively; however, Seelos Therapeutics faced a 52% drop after a delisting notice.

Market Overview: U.S. stocks opened lower with the Dow Jones down approximately 200 points, while real estate shares rose by 0.9% and energy shares fell by 2.6%. Bank of America reported better-than-expected earnings but saw a year-on-year net income decline.

Global Market Trends: European shares showed mixed results, Asian markets mostly closed lower, and commodities like oil decreased by 5%. The NY Empire State Manufacturing Index also declined significantly, indicating economic contraction.